Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03017846 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
A Phase 2 study of Molluscum Contagiosum, sponsored by Steven R Cohen.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03017846: Completed Phase 2 study of Molluscum Contagiosum, sponsored by Steven R Cohen.
NCT03017846 is a Phase 2 study of Molluscum Contagiosum that has completed, run by Steven R Cohen. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03017846, a Phase 2 study of Molluscum Contagiosum, has completed, sponsored by Steven R Cohen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Cantharidin is cited in the dermatology and pediatric literature as a valuable treatment option. Treatment is often available in private practice offices, where a prescribing physician may offer a non-FDA approved treatment on an individualized basis. The situation is different in many hospital and academic settings, such as our own for example, where the formulary is defined through a FDA-approved indication. The absence of an indication precludes its addition to many hospital formularies, thus limiting the options available to a prescribing physician and denying patient access to a treatment offered in the private practice setting. An indication and formulary status require controlled clinical trials on the safety and efficacy of cantharidin in MC. The objective of this trial is to see if this commercially-viable cantharidin formulation has a comparable safety and efficacy profile as formulations previously studied under conditions which most closely match the what has been historically done in the clinic.
Primary Outcome
100% reduction in baseline lesion count
Conditions Studied
Interventions
- DRUG Cantharidin
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-09-06 |
| Phase | Phase 2 |
What the finished NCT03017846 record still lists
NCT03017846 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Molluscum Contagiosum appearing as the primary indexed condition, and to 1 intervention - of which Cantharidin is the first listed.
NCT03017846 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03017846 about?
NCT03017846 is a clinical study titled "Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2". Cantharidin is cited in the dermatology and pediatric literature as a valuable treatment option. Treatment is often available in private practice offices, where a prescribing physician may offer a non-FDA approved treatment on an individualized basis. The situation is different in many hospital and ...
What is the current status of trial NCT03017846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2016-09. Estimated completion is 2017-09-06.
What conditions does trial NCT03017846 study?
This clinical trial studies the following conditions: Molluscum Contagiosum.
What interventions are being tested in trial NCT03017846?
The interventions under investigation include: Cantharidin (DRUG).
Who is sponsoring clinical trial NCT03017846?
This trial is sponsored by Steven R Cohen, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03017846 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Molluscum Contagiosum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03017846's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia